VistaGen Therapeutics receives FDA fast track designation for development of AV-101 as a non-opioid treatment for neuropathic pain

VistaGen Therapeutics

3 October 2018 - Second FDA fast track designation for AV-101 since December 2017 marks another milestone for VistaGen's R&D pipeline.

VistaGen Therapeutics today announced that the U.S. FDA has granted fast track designation for development of AV-101 as a non-opioid, non-sedating treatment for neuropathic pain. This is the second FDA fast track designation granted to VistaGen since December 2017.

AV-101 is an investigational, orally bioavailable, small molecule NMDA (N-methyl-D-aspartate) receptor glycine B antagonist without psychological or sedative side effects.

Read VistaGen Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track